Drug Information

Drug General Information
Drug ID
D00YPO
Former ID
DNC004302
Drug Name
TETRAHYDROBENXIMIDAZOLE
Drug Type
Small molecular drug
Indication Discovery agent Investigative [533015]
Formula
C18H20N4O
Canonical SMILES
CC1CC(=O)NN=C1C2=CC=C(C=C2)N3C=NC4=C3CCCC4
InChI
1S/C18H20N4O/c1-12-10-17(23)20-21-18(12)13-6-8-14(9-7-13)22-11-19-15-4-2-3-5-16(15)22/h6-9,11-12H,2-5,10H2,1H3,(H,20,23)
InChIKey
KDEKNYKHIZTSLE-UHFFFAOYSA-N
PubChem Compound ID
14032753
Target and Pathway
Target(s) CGMP-inhibited 3',5'-cyclic phosphodiesterase A Target Info Inhibitor [533015]
KEGG Pathway Purine metabolism
cGMP-PKG signaling pathway
cAMP signaling pathway
Morphine addiction
Reactome cGMP effects
G alpha (s) signalling events
WikiPathways miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
References
Ref 533015J Med Chem. 1989 Feb;32(2):342-50.Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.
Ref 533015J Med Chem. 1989 Feb;32(2):342-50.Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.